HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Delgado, M. Articles by Ganea, D. Search for Related Content PubMed PubMed Citation Articles by Delgado, M. Articles by Ganea, D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

Inhibition of Endotoxin-Induced Macrophage Chemokine Production by Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide In Vitro and In Vivo¹

Mario Delgado^*, and Doina Ganea^*,2

^* Department of Biological Sciences, Rutgers University, Newark, NJ 07102; and Departamento Biologia Celular, Facultad de Biologia, Universidad Complutense, Madrid, Spain

Inflammatory chemokines recruit various populations of immune cells that initiate and maintain the inflammatory response against foreign Ags. Although such a response is necessary for the elimination of the Ag, the inflammation has to be eventually resolved in a healthy organism. Neuropeptides such as vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP), released after antigenic stimulation, contribute to the termination of an inflammatory response primarily by inhibiting the production of proinflammatory cytokines. Here we investigated the effects of VIP and PACAP on chemokine production. We report that VIP and PACAP inhibit the expression of the macrophage-derived CXC chemokines macrophage inflammatory protein-2 and KC (IL-8), and of the CC chemokines MIP-1, MIP-1, monocyte chemoattractant protein 1, and RANTES in vivo and in vitro. The inhibition of chemokine gene expression correlates with an inhibitory effect of VIP/PACAP on NF-B binding and transactivating activity. The VIP/PACAP inhibition of both chemokine production and of NF-B binding and transactivating activity is mediated through the specific VIP receptor VPAC1, and involves both cAMP-dependent and -independent intracellular pathways. In an in vivo model of acute peritonitis, the inhibition of chemokine production by VIP/PACAP leads to a significant reduction in the recruitment of polymorphonuclear cells, macrophages, and lymphocytes into the peritoneal cavity. These findings support the proposed role of VIP and PACAP as key endogenous anti-inflammatory agents and describe a novel mechanism, i.e., the inhibition of the production of macrophage-derived chemokines.

This article has been cited by other articles:

				V. S. Conlin, X. Wu, C. Nguyen, C. Dai, B. A. Vallance, A. M. J. Buchan, L. Boyer, and K. Jacobson Vasoactive intestinal peptide ameliorates intestinal barrier disruption associated with Citrobacter rodentium-induced colitis Am J Physiol Gastrointest Liver Physiol, October 1, 2009; 297(4): G735 - G750. [Abstract] [Full Text] [PDF]

				L. Lajavardi, A. Bochot, S. Camelo, B. Goldenberg, M.-C. Naud, F. Behar-Cohen, E. Fattal, and Y. de Kozak Downregulation of Endotoxin-Induced Uveitis by Intravitreal Injection of Vasoactive Intestinal Peptide Encapsulated in Liposomes Invest. Ophthalmol. Vis. Sci., July 1, 2007; 48(7): 3230 - 3238. [Abstract] [Full Text] [PDF]

				P. Goichberg, A. Kalinkovich, N. Borodovsky, M. Tesio, I. Petit, A. Nagler, I. Hardan, and T. Lapidot cAMP-induced PKC{zeta} activation increases functional CXCR4 expression on human CD34+ hematopoietic progenitors Blood, February 1, 2006; 107(3): 870 - 879. [Abstract] [Full Text] [PDF]

				D. POZO and M. DELGADO The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide? FASEB J, September 1, 2004; 18(12): 1325 - 1334. [Abstract] [Full Text] [PDF]

				M. Delgado, D. Pozo, and D. Ganea The Significance of Vasoactive Intestinal Peptide in Immunomodulation Pharmacol. Rev., June 1, 2004; 56(2): 249 - 290. [Abstract] [Full Text] [PDF]

				H. Jing, E. Vassiliou, and D. Ganea Prostaglandin E2 inhibits production of the inflammatory chemokines CCL3 and CCL4 in dendritic cells J. Leukoc. Biol., November 1, 2003; 74(5): 868 - 879. [Abstract] [Full Text] [PDF]

				M. Delgado, J. Leceta, and D. Ganea Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia J. Leukoc. Biol., January 1, 2003; 73(1): 155 - 164. [Abstract] [Full Text] [PDF]

				D. Ganea and M. Delgado VASOACTIVE INTESTINAL PEPTIDE (VIP) AND PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AS MODULATORS OF BOTH INNATE AND ADAPTIVE IMMUNITY Critical Reviews in Oral Biology & Medicine, May 1, 2002; 13(3): 229 - 237. [Abstract] [Full Text] [PDF]

				C. Abad, C. Martinez, J. Leceta, R. P. Gomariz, and M. Delgado Pituitary Adenylate Cyclase-Activating Polypeptide Inhibits Collagen-Induced Arthritis: An Experimental Immunomodulatory Therapy J. Immunol., September 15, 2001; 167(6): 3182 - 3189. [Abstract] [Full Text] [PDF]